September 4, 2019 | Vensana in the News

Co-founded by Versant, NEA investors, new medtech VC firm kicks off inaugural fund with $225M bounty

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

39

Level I Clinical Trials

31

Strategic Financings

31

Exits by IPO or M&A